| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Endocrinology, Vol 130, 2067-2075, Copyright © 1992 by Endocrine Society
ARTICLES |
LJ Rosolowsky and WB Campbell
University of Texas Southwestern Medical Center, Department of Pharmacology, Dallas 75235-9041.
The adrenal cortex contains a kallikrein-like enzyme that may lead to bradykinin (BK) formation. This study was designed to determine whether BK acts on adrenocortical cells to stimulate steroid secretion. BK, Lys- BK, a specific BK 2 (B2) receptor agonist, and desArg9-BK, a specific BK 1 (B1) receptor agonist, all stimulated aldosterone secretion from cultured bovine adrenal zona glomerulosa cells. BK and Lys-BK were equipotent (EC50 = 2 x 10(-9) M), whereas desArg9-BK was 1000-fold less potent. The maximal effects of BK and BK analogs were comparable to the maximal effects of adrenocorticotropin or angiotensin II. A B2, but not a B1, receptor antagonist inhibited BK-stimulated aldosterone release. Verapamil and N,N-diethylamino-octyl-3,4,5-trimethoxybenzoate, which reduce intracellular calcium concentrations, reduced BK-stimulated aldosterone secretion. Although BK stimulated both prostacyclin and aldosterone production, indomethacin abolished prostacyclin production without affecting aldosterone secretion. In cultured adrenal fasciculata cells, high concentrations of BK stimulated cortisol release, but B1 or B2 receptor agonists were not effective. BK- stimulated cortisol secretion was reduced by N,N-diethylamino-octyl- 3,4,5-trimethoxybenzoate but not by indomethacin. In summary, BK stimulates aldosterone release from cultured adrenal glomerulosa cells via high affinity B2 receptors. The effect is calcium-dependent and independent of prostaglandins. BK also increases cortisol release; however, this stimulation requires high concentrations of BK and may be mediated by an unknown receptor or by a receptor-independent mechanism.
This article has been cited by other articles:
 |
|
 |
|
  C. J. Hanke, B. B. Holmes, Y. Xu, K. Nithipatikom, and W. B. Campbell Endothelium-Derived Steroidogenic Factor Enhances Angiotensin II-Stimulated Aldosterone Release by Bovine Zona Glomerulosa Cells Endocrinology, January 1, 2007; 148(1): 317 - 323. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Nithipatikom, B. B. Holmes, M. J. McCoy, C. J. Hillard, and W. B. Campbell Chronic administration of nitric oxide reduces angiotensin II receptor type 1 expression and aldosterone synthesis in zona glomerulosa cells Am J Physiol Endocrinol Metab, November 1, 2004; 287(5): E820 - E827. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. SPAT and L. HUNYADY Control of Aldosterone Secretion: A Model for Convergence in Cellular Signaling Pathways Physiol Rev, April 1, 2004; 84(2): 489 - 539. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. J. Murphey, S. Kumar, and N. J. Brown Endogenous Bradykinin and the Renin and Pressor Responses to Furosemide in Humans J. Pharmacol. Exp. Ther., November 1, 2000; 295(2): 644 - 648. [Abstract] [Full Text]
|
|
|
|
|
|
L. J. Rosolowsky, C. J. Hanke, and W. B. Campbell Adrenal Capillary Endothelial Cells Stimulate Aldosterone Release through a Protein That Is Distinct from Endothelin Endocrinology, October 1, 1999; 140(10): 4411 - 4418. [Abstract] [Full Text]
|
|
|
|
 |
|
 A. K. Laflamme, L. Oster, R. Cardinal, and J. de Champlain Effects of Renin-Angiotensin Blockade on Sympathetic Reactivity and ß-Adrenergic Pathway in the Spontaneously Hypertensive Rat Hypertension, August 1, 1997; 30(2): 278 - 287. [Abstract] [Full Text]
|
|
|
|
 |
|
 D. G Kiely, R. I Cargill, N. M Wheeldon, W. J Coutie, and B. J Lipworth Haemodynamic and endocrine effects of type 1 angiotensin II receptor blockade in patients with hypoxaemic cor pulmonale Cardiovasc Res, January 1, 1997; 33(1): 201 - 208. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |
